[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100570946":3},{"organization":4,"armGroups":7,"interventions":8,"overallOfficials":7,"centralContacts":13,"locations":23,"responsibleParty":43,"collaborators":47,"id":62,"slug":63,"hasResults":64,"nctId":65,"briefTitle":66,"officialTitle":67,"acronym":68,"eligibilityCriteria":69,"healthyVolunteers":64,"sex":70,"minAge":71,"maxAge":7,"enrollmentInfo":72,"targetDuration":7,"studyType":75,"phases":7,"briefSummary":76,"conditions":77,"keywords":80,"overallStatus":25,"whyStopped":7,"lastUpdateSubmitDate":83,"lastUpdatePostDateStruct":84,"startDateStruct":87,"completionDateStruct":89,"leadSponsor":91,"locationsCount":92},{"fullName":5,"class":6},"Liyuan Hospital of Tongji Medical College, Huazhong University of Science and Technology","OTHER",null,[9],{"type":10,"name":11,"description":12,"armGroupLabels":7,"otherNames":7},"DEVICE","Shockwave balloons","To evaluate the effectiveness and safety of the Shockwave intraperipheral shockwave catheter system in peripheral arterial angioplasty.",[14,19],{"name":15,"role":16,"phone":17,"phoneExt":7,"email":18},"Zibo Feng, MD","CONTACT","86-13545160302","fengzibo@hust.edu.cn",{"name":20,"role":16,"phone":21,"phoneExt":7,"email":22},"Ye Du, DM","86-15827105515","duye@hust.edu.cn",[24],{"facility":5,"status":25,"city":26,"state":27,"zip":7,"country":28,"countryCode":29,"cosmosGeoPoint":30,"geoPoint":35,"contacts":36},"RECRUITING","Wuhan","Hubei","China","CN",{"type":31,"coordinates":32},"Point",[33,34],114.26667,30.58333,{"lat":34,"lon":33},[37,38,40],{"name":15,"role":16,"phone":17,"phoneExt":7,"email":18},{"name":39,"role":16,"phone":21,"phoneExt":7,"email":22},"Ye Du, MD",{"name":41,"role":42,"phone":7,"phoneExt":7,"email":7},"Youpeng Zhu, MD","SUB_INVESTIGATOR",{"type":44,"investigatorFullName":45,"investigatorTitle":46,"investigatorAffiliation":5,"oldNameTitle":7,"oldOrganization":7},"PRINCIPAL_INVESTIGATOR","Zibo Feng","Professor",[48,50,52,54,56,58,60],{"name":49,"class":6},"Shanghai Zhongshan Hospital",{"name":51,"class":6},"Huashan Hospital",{"name":53,"class":6},"Xuanwu Hospital, Beijing",{"name":55,"class":6},"The General Hospital of Southern Theater Command",{"name":57,"class":6},"Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine",{"name":59,"class":6},"RenJi Hospital",{"name":61,"class":6},"Chengdu University of Traditional Chinese Medicine","100570946","angioplasty-with-shockwave-ivl-catheter-system-in-femoropopliteal-lesions-100570946",false,"NCT06713850","Angioplasty With Shockwave IVL Catheter System in Femoropopliteal Lesions","Real-World Clinical Evaluation of the Shockwave Intravascular Lithotripsy (IVL) Catheter System for Treating Severe Calcified Lesions in Femoropopliteal Arteries","SHIELD","Inclusion Criteria:\n\n\\-\n\n1\\) Age ≥ 18 years (2) Rutherford Classification 2-5 3) Stenosis (\\>70% stenosis confirmed by digital subtraction angiography (DSA) imaging) or occlusion of the femoropopliteal artery, with one healthy patent outflow tract distal to the knee in continuity with a patent outflow tract below the ankle.\n\n(4) Patients who understand the purpose of the study, participate in the experiment voluntarily, sign the informed consent form and are willing to be followed up.\n\n5\\) The guidewire needs to pass through the lesion; 6) Life expectancy \\>24 months 7) Moderately severe calcified lesions confirmed by imaging data: 8) For patients who receive intervention in both lower extremities may be enrolled in order of time of intracavitary treatment 9) For combined aortoiliac artery lesions that have undergone endoluminal revascularization to achieve flow recanalization without more than 50% residual stenosis.\n\nExclusion Criteria:\n\n1. Patients with stroke, cerebral hemorrhage, gastrointestinal hemorrhage, or cardiac infarction within 3 months prior to enrollment (2) Patients with known allergy to heparin, aspirin, other antiplatelet drugs, contrast agents, etc.\n\n3\\) Patients who have been enrolled in medications that interfere with this clinical trial within the last 3 months or who have been treated intraoperatively with other special vascular bed preparation devices, such as plaque volume reduction devices, special balloons, and so on; 4) Pregnant and lactating women 5) Patients who are unable or unwilling to participate in this trial. 6) patients with Berger's disease 7) patients who have received arterial bypass diversion on the treated side","ALL","18 Years",{"count":73,"type":74},130,"ESTIMATED","OBSERVATIONAL","There is a lack of prospective observational studies of shockwave balloons in the treatment of moderate-to-severe calcification of the femoral popliteal artery at the international level. Therefore, in this study, we wish to set up a real-world study of shockwave balloon in the treatment of moderate-to-severe calcification to investigate the real-world efficacy of shockwave balloon in the treatment of moderate-to-severe calcified lesions.",[78,79],"Peripheral Artery Disease (PAD)","Chronic Limb Threatening Ischemia",[81,79,82],"Peripheral Artery Disease","Severe calcification","2024-11-27",{"date":85,"type":86},"2024-12-03","ACTUAL",{"date":88,"type":74},"2024-12-01",{"date":90,"type":74},"2028-11",{"name":5,"class":6},1]